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There are currently ~600,000 Canadians with end stage heart failure. Although medications are 
effective, the ideal treatment would be heart transplantation. Loss of blood (ischemia) to the 
organ during preservation and restoration of blood flow (reperfusion) leads to ischemia 
reperfusion injury (IRI) which can lead to cell death. Circular RNA is a new type of non-coding 
RNA forming a covalently closed loop single stranded RNA. Evidence suggests circular RNA 
Hipk3 (circHIPK3) generated from exon 2 of the Hipk3 gene is involved in many pathologies. 
However, the role of circHIPK3 in IRI has not been investigated. Using our in vitro IRI model, 
we showed that CircHIPK3 expression is increased during IRI and knockdown increased cell 
death. In addition, circHIPK3 knockdown exacerbated pro-apoptotic Bax mRNA levels, caspase 
3 activation and MLKL phosphorylation. We also observed no significant changes in 
inflammatory response following circHIPK3 knockdown and IRI. In conclusion, the loss of 

















Heart diseases is a leading cause of death world-wide and the second leading cause of death in 
Canadians. Although we have developed many successful treatments for end-stage heart failure, 
the best treatment would be to replace the organ with a heart transplantation. However, loss of 
blood flow (ischemia) for long periods and restoring of blood (reperfusion) can leading to 
ischemia reperfusion injury (IRI) and cause the cells and the organ to die or exert extra damage 
in the recipient. IRI is a large barrier that prevents many hearts being viable from donors, with 
only 24% of donors having a viable heart. Therefore, the need to help the success rate of 
transplant surgeries and increase the availability of donors is immense. A new molecule known 
as circular RNA (circRNA) involvement in human disease is becoming increasingly important. 
CircRNA can act as a regulator by effecting other types of RNA or proteins involved in many 
diseases. Circular RNA Hipk3 (circHIPK3), has been identified as a key centre point in cell 
survival. However, circHIPK3s role in IRI has not been studied. Our research shows that 
circHIPK3 expression can directly influence the outcome of successful preservation. Our results 
showed that decreases in circHIPK3 leads to increased death during reperfusion and provides 
worse outcomes. This suggests that circHIPK3 plays a vital role in IRI and that its levels may be 
useful to determine the difference between successful and unsuccessful organ preservation. 
Success of this research will provide insight into previously unknown targets for IRI treatment 
and help develop new therapies. This in turn will allow us to increase the availability of heart 
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Chapter 1. Introduction to Ischemia Reperfusion Injury and Circular 
RNA 
1.1 Heart Disease and the Need for Heart Transplantation 
Heart disease remains the second leading cause of death in Canada, killing 51,000-53,000 
Canadians per year between 2015-20191. The death toll from heart disease is on the rise, 
where 48,757 cardiac related deaths occurred in 2010 compared to the 52,541 in 2019 
(Figure 1.1).  


























Figure 1.1: Number of cardiac related deaths per year in Canada showing increasing 
trend over time. Data obtained from stats Canada1. 
In 2013 it was estimated that 2.4 million Canadians were living with diagnosed heart 
disease (HD) a steep rise from the 1.5 million in 2001. Although the prevalence of HD in 
Canadians and absolute deaths has risen, the percentage of deaths has dropped with an 




signs and symptoms. As survival rates of acute myocardial injuries and conditions 
increases, the number of patients who develop end stage heart failure or congestive heart 
failure increases. Patients who survive acute HD are six times more likely to develop 
structural changes in the heart and symptoms associated with end stage heart failure, in 
which the heart lacks the ability to pump blood and supply the other organs and body with 
the oxygen and nutrients required (Figure 1.2).  
 
Figure 1.2 Typical progression of heart disease from at risk conditions to congestive 
heart failure.  
It is estimated that there are currently 600,000 Canadians living with heart failure, with an 
increasing incidence there is an increased demand for transplantation.2 Although most 
cases can be managed by lifestyle, medications or minor surgical procedures, when these 
treatments fail patients may be candidates for heart transplantation. In 2011, the Canadian 
Cardiac Transplant Network published a report for eligibility of recipients in Canada. 
They cited any late stage heart failure as criteria for recipients to be eligible, given there 
are no pre-existing conditions that would cause heart failure immediately or poor surgical 




of eligible donors. In 2019, there were a total of 346 patients placed on the waiting list, 
189 of which received heart transplantation.4 This translates to 54.6% of patients 
receiving a transplant however, their length of time on the waitlist is not listed, which 
could span months to years.  In the coming years as the prevalence of end stage heart 
failure increases, the need for heart transplantation and eligible donors will increase.  
1.2 Heart Transplantation Availability and the Ischemia Reperfusion Barrier 
Ischemia reperfusion injury (IRI) characterized by loss of blood (ischemia) and full 
restoration of blood flow (reperfusion) can lead to cell death and tissue damage and 
remains a large barrier of eligible donors for heart transplantation. Due to this barrier, the 
availability of viable hearts from organ donors is largely diminished. In 2018, of the 189 
heart transplantations performed in Canada, only 24% of donors were classified as 
previously deceased while 0% of donors were classified as donor after circulatory death 
(DCD) (Table 1.1).4 In contrast, in 2018 there was 1706 kidneys transplanted throughout 
Canada, 86% of these transplantations were from previously deceased donors compared 
to the 24% of cardiac transplants. In addition, 30% of donors were classified as DCD, 
which represents approximately 29% of all deceased donors (Table 1.1). The inability to 
use a large percentage of deceased donors and DCD largely limits the availability of 
hearts. DCD and deceased donors are not considered eligible due to the increased IRI and 
risk of worse outcomes. During ideal organ preservation, the donor body is cooled and the 
steps to preserve the organ are taken prior to ischemia occurring, where as in DCD the 
ischemia period begins prior to preservation leading to periods of warm ischemia which 
can be detrimental to organ viability after reperfusion.5 There is a clear relationship 




failure6,7, along with revascularization and direct myocardial infarction.8,9 Therefore, to 
increase the availability of donor hearts, it needs an effective strategy to mitigate IRI and 
improve organ preservation in cardiac transplantation.  
Table 1.1 Percentage of each organ used for donation from a donor.  
Organ type 
Proportion of deceased donors having 
an organ used for transplantation 
Proportion 
of organs 
from DCD  
Kidney 
86% at least one kidney  
79% both kidneys 
30% 
Liver 60% 10% 
Heart 24% 0% 
Lung 
42% at least one lung  
38% both lungs 27% 
Pancreas 9% 10% 
 
1.3 Ischemia Reperfusion Injury and Reactive Oxygen Species Generation 
Ischemia reperfusion injury, where periods of ischemia lead to organ death yet full 
reperfusion leads to further tissue injury, remains an important paradox and concept that 
challenges organ transplant for the past 50 years8. It is well known that ischemia leads to 
organ dysfunction through depletion of cellular ATP due to lack of mitochondrial 
function in which tissues becomes necrotic and undergo irreversible cell death5,8,10–12. 
Therefore, guidelines and procedures have been developed to assist in minimizing 
ischemia times and predict which organs are viable. The standard of care for cardiac 
transplantation currently revolves around the concept of preventing ischemia before organ 
preservation begins and mitigating ischemic times by restoring blood flow quickly5,6,12–14. 
Although procedures and preservation methods such as cardioplegia solutions such as 




the time between donor harvest and transplantation in a recipient takes several hours. This 
means ischemia is not fully mitigated and although necrosis rarely occurs, the effects of 
reperfusion injury are always present. Reperfusion injury is driven primarily by the acute 
increased generation of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) after reintroduction of oxygen as mitochondria begin to produce ATP again8,10,17. 
This sudden and increased generation of ROS/RNS out paces the cellular ability to 
detoxify these substances, creating an imbalanced redox signalling pathway.8,18 Part of 
this imbalance is generated in early ischemia, where cellular metabolism shifts from 
oxidative phosphorylation and Beta-oxidation to make ATP through anaerobic methods 
such as glycolysis at the expense of reductive molecules, leaving the NADH/NAD+ ratio 
to increase and the cellular ability to remove free radicals impaired19. Under normal 
conditions, ROS such as 𝑂2
•− are generated in low amounts through electron leakage of 
the inner mitochondrial membranes during oxidative phosphorylation20–22. Any free 
radicals that are generated quickly undergo single electron reduction to generate stable 
molecules. The exact mechanism depends on their location within the mitochondria, 
while both the matrix and intermembrane space both contain superoxide dismutase, the 
intermembrane space contains cytochrome C and the Q0 site of complex III, while the Qi 
site of complex IIII is orientated towards the matrix20,23,24. During ischemia, there is a 
modest increase in free radicals, but more importantly there is an impairment of 
cytochrome oxidase dimer formation and a depletion of cytochrome C25, impairing the 
scavenging of ROS in the mitochondrial matrix and intermembrane space. In addition, 
superoxide dismutase interacts with 𝑂2
•− and yields larger proportions of H2O2, which 
accumulate in the cell and activate RNS8,21,22. Although there is a shift in generation of 
ROS during ischemia, this pathway is self-limiting as the primary 𝑂2




presence of O2, in which there is none and the ROS levels do not near fatal limits
26,27. 
High levels of ROS are only achieved during reperfusion phase in which oxygen is 
reintroduced to mitochondria and 𝑂2
•− can once again be generated, but at greater quantity 
than prior to ischemia. Once ROS during reperfusion reach a high enough threshold, they 
induce cellular damage and death through activation of proteolytic enzymes, 
metalloproteases, membrane damage and further mitochondrial dysfunction28. Therefore, 
it is the shift of available O2 to ROS and the inhibition of ROS detoxification during 
ischemia and the restoration of O2 and ROS generation during reperfusion that drive IRI 
and fatal limits of ROS.  
1.4 Ischemia Reperfusion Injury Induced Cell Death  
 Prolonged ischemia reperfusion injury is capable of inducing significant cellular 
stress and eventual death. Typically, there are four modes of cell death during IRI. 
Necrosis and necroptosis share a pro-inflammatory form of cell death, while apoptosis 
and mitoptosis share more regulated and controlled form of cell death11. Necroptosis and 
necrosis share similar characteristics such as cellular swelling, membrane permeability 
and lack of chromatin. Where apoptosis and mitoptosis are controlled forms of cell death 
resulting in shrinkage of cellular bodies, pyknosis of the nucleus and controlled 
degradation of cellular components29. Mitoptosis refers directly to death of mitochondria 
leading to apoptosis and/or autophagy: controlled degradation of the own cell. While 
apoptosis can occur both in a mitoptosis dependent or independent manner, apoptosis is 
energy-dependent and requires a series of molecular checkpoints driven by proteolytic 
cleavage and enzyme activation18,29,30. There are three characterized apoptotic pathways, 




regarded as the mitochondrial activation pathway, and granzyme pathway which is 
regulated through T-cell activation29. Due to the similarities between necroptosis and 
necrosis, along with mitoptosis’ dependency on apoptosis, we have chosen to focus on 
necroptosis and apoptosis throughout this thesis.  
1.4.1 Intrinsic and Extrinsic Apoptosis   
 During IRI, the extrinsic and intrinsic pathways both show activation and have an 
interplay previously thought to be mutually exclusive29–31. During reperfusion as ROS 
reach fatal levels and the pH rises within the mitochondria the mitochondria permeability 
transition pore (mPTP) begins to open18,32. mPTP activation can occur through membrane 
integrity loss due to ROS damage causing Ca2+ overload31,33 or activation of B-cell 
lymphoma 2 (Bcl-2) protein family18,31,32,34. Bcl-2 family of pro-apoptotic proteins 
initiates mPTP through the oligomerization of Bcl-2 associated X protein (Bax) and Bcl-2 
homologous antagonist killer (Bak), allowing cytochrome C and ROS release from 
mitochondrial matrix to the cytosol33. Other Bcl-2 family proteins such as B-cell 
lymphoma-extra large (Bcl-XL) play an anti-apoptotic role aimed at preventing 
cytochrome C release and can be targeted to prevent or exacerbate intrinsic apoptosis. 
The terminal end of the intrinsic apoptotic signalling pathway is marked by cytochrome C 
release and procaspase 9 aggregation and subsequent activation to caspase 9. The 
extrinsic pathway of apoptosis is mediated through binding of ligands to death receptors 
and caspase activation. The most well defined of these are the TNFα/TNF receptor 1 and 
Fas Ligand/Fas Receptor. In the extrinsic model, activation of receptor proteins results in 
TRADD and/or FADD recruitment and association with procaspase 8 forming the death 




subsequent activation at the terminal end of the extrinsic signalling pathway29,31. 
Regardless of intrinsic or extrinsic activation, both apoptotic signalling pathways end 
with the activation of effector caspases such as caspase 3. Effector caspase activation 
marks the beginning of the execution pathway, in which endonucleases, proteases, and 
degradation of cellular component begin along with morphological change29,31,36.  
1.4.2 Caspase Independent Form of Cell Death  
 An alternative form of cellular death induced by IRI is necroptosis. Necroptosis is 
a programmed cell death that is independent of caspase activation and appears to be 
exclusive with extrinsic apoptotic signalling. During necroptosis, TNFα induced FADD 
activation recruits receptor-interaction serine/threonine kinase 1 (RIP1) and receptor-
interaction serine/threonine kinase 3 (RIP3) cross-phosphorylation and their complex 
formation of the necrosome37–39. The necrosome then leads to phosphorylation of mixed 
lineage kinase domain like protein (MLKL)37. P-MLKL along-side necrosome formation 
is responsible and essential for necroptosis and cell death that is mechanistically and 
physiologically distinct from apoptosis. Both RIP1 and RIP3 are known targets of caspase 
8 cleavage40,41, suggesting that activation of extrinsic apoptosis is mutually exclusive, or 
at least not inducing of necroptosis, while intrinsic apoptosis can co-exist in theory. A 





Figure 1.3 Graphical summary of intrinsic (right) and extrinsic (centre) apoptotic 
signalling and their interaction with necroptosis (left). 
1.5 Current Treatment and Protective Strategies for Ischemia Reperfusion Injury 
 IRI remains a leading complication during cardiac transplantation and although 
research progress in the past 40 years has been successful in mitigating IRI to some 
extent, no standard of care or drugs have been accepted world-wide. The initial treatment 
for IRI is recognized as ischemic pre-conditioning in which small episode of ischemia is 
used to produce a cardio protective effect prior to an induction of a long ischemic 
episode. This was first observed in 1986 where smaller infarct size was observed 
following long term ischemia in samples which had smaller intervals prior42. There is 
evidence suggesting changes in metabolic state which provide protective effects for up to 
72 h following pre-conditioning43–45. Although mechanistically pre-conditioning is 
complex and not well understood, there are theories supporting it dampens the burst of 
ROS during reperfusion phase as well as increasing pro-survival signals such as ERK1/2 




sensitive Potassium (KATP) channels during pre-conditioning is thought to be important 
for mitochondrial stability and reduce Ca2+ over-loading and influx during ischemic 
insult, lowering MPTP formation and leading to protection against long term hypoxia46,47. 
Although pre-conditioning is a promising treatment that has been shown experimentally 
and clinically, it can only be applied in situations where long-term ischemia can be 
anticipated such as cardiac by-pass surgery. This makes it more complicated to involve 
during organ transplantation where anticipation is not always possible especially with 
previously deceased patients. Therefore, alternative treatments have been a focus of 
research for the past 30 years.  
 Preventing mPTP formation through ROS scavenging is a thoroughly researched 
concept in cardiac surgery8. Increasing endogenous levels of natural antioxidants has been 
tried and shown potential, but sometimes it can be deleterious due to the absence of any 
redox signalling of pro-survival signals prior to ischemia. Therefore, emphasis on 
external drugs such as N-actylcysteine, ebselen, allopurinol and α-tocopherol has been 
tested8,18,48,49. Experimental evidence suggests these are effective at scavenging and 
reducing ROS during IRI, but due to the low efficacy of delivery to the mitochondria in 
situ, their clinical applicability limited. Other compounds designed with mitochondrial 
targeting abilities such as mitoquinone have been shown to be effective when delivered 
prior to IRI18,50. More recently, AP39, a hydrogen sulfide releasing agent has shown 
efficacy at protecting against IRI in kidney51, although its effect on cardiac IRI remain 
primitively studied52. 
 It is clear in the past 50 years much progress at understanding and protecting 




clear solution or standard that can completely mitigate IRI as many treatments are 
situationally dependent or require specific routes of administration that may be 
unfeasible. Therefore, new treatments and regulators of IRI are needed.  
1.6 Circular RNA: a new type of non-coding RNA 
 Circular RNA (CircRNA) are a novel non-coding RNA that have become an 
increasing topic of interest involved in the pathogenesis of diseases53,54. CircRNA was 
first observed in 1976 under electron microscopy and recognized as nothing more than 
mis-splicing and splicing errors55. However, recent advances in molecular biology 
techniques and bioinformatics pipelines have led to their re-discovery as important, and 
possible the largest family, of non-coding RNAs with an estimate of  >20,000 unique 
human CircRNAs56,57. Although the estimated amount of CircRNA remains theoretically 
possible, it is likely a smaller subset of them are transcribed in vivo at biologically 
relevant levels. CircRNAs are a single stranded covalently closed loops of RNA, 
characterized by their lack of polarity, poly-A tail and stability in vivo58,59. CircRNA are 
generated through a process known as back-splicing of the pre-mRNA using the 
canonical splicing machinery and competes with mRNA biogenesis58. In canonical 
splicing, a conserved GU element at the 5’ end of the intron and an AG at the 3’ end; 
termed the donor and acceptor site respectively are crucial for exon joining53,60. The 
protein-mRNA complex known as the spliceosome, catalyzes the nucleophilic attack of a 
2’ OH of an adenosine molecule 20-50 nucleotides upstream of the acceptor site known 
as the branching point onto the 5’ phosphate of the donor site61. This attack forms a 
covalent loop known as the lariat. The newly free 3’ OH of the upstream exon attacks the 




back-splicing, CircRNA have been proposed to be formed through two mechanisms: 
direct backs-splicing or exon skipping58,61. In exon skipping of a 3-exon pre-mRNA, the 
branching point of intron 2 would attack the donor site of intron 1, followed by the attack 
of the 3’OH from exon 1 onto the acceptor site of intron 253,58. This would result in the 
joining of exons 1 and 3, with the release of introns 1, 2 and exon 2 as the lariat. The 
resulting circRNA may contain exon/intron sequences or undergo further nucleophilic 
attack to allow the release of exon 2 as CircRNA, and an intronic lariat by-product53,59. In 
direct back-splicing of a similar pre-mRNA, the pre-mRNA molecule will form a 
secondary structure between introns 1 and 2. The branching point of intron 1 will attack 
the donor site of intron 2, resulting in a 3’OH on exon 2. The 3’OH attacks the acceptor 
site on intron 1, releasing exon 2 as a CircRNA, and a terminated fork product59. A 








Figure 1.4 Simplified example of back-splicing to produce exon-exon joining compared 
to exon circularization. 
1.7 Circular RNA Hipk3: A Highly Abundant and Distributed Circular RNA 
 Recently, a circular RNA derived from exon 2 of homeodomain-interacting 
protein kinase 3 (Hipk3), termed circular RNA Hipk3 (circHIPK3), has become an 
increasing target of interest for therapeutic research. The biogenesis of circHIPK3 has 
been partially eluted. Recent studies suggest the secondary structure of the pre-mRNA-
spliceosome complex is mediated through short intronic repeat sequences (SIRS) in the 
flanking introns56,62. Zheng et al showed SIRS to be crucial for circHIPK3 biogenesis56. 
Flanking intron analysis of exon 2 of HIPK3 showed complementary 28 SIRS upstream 
and 51 SIRS downstream of circHIPK3. Two SIRS elements immediately flank exon 2 of 
HIPK3 upstream and downstream. Subsequent deletion suggests that the downstream 
SIRS are crucial for circHIPK3 biogenesis56. Interestingly, upstream SIRS mutations had 




facilitate a similar circularization reaction, which was confirmed by CRISPR/Cas9 
knockout of intronic repeats56. The mutations of intronic sequences reportedly had no 
effect on HIPK3 mRNA production, but showed significant downregulation of 
circHIPK3, indicating that SIRS elements are crucial for circHIPK3 biogenesis. Other 
circRNA variants of the HIPK3 gene have been detected however, their relatively 
abundance is low when compared with circHIPK3 derived solely of exon 256. More 
recently, RNA binding protein quaking (QKI) has been shown to play an important role 
in circRNA biogenesis, by binding to QKI response elements in the flanking introns63,64. 
Addition or deletion of QKI response elements is sufficient to promote/diminish but not 
abolish circRNA biogenesis63. Therefore, it is likely both SIRS elements and RNA 
binding proteins are essential for circRNA biogenesis. However, the presence of QKI 
response elements and QKI function on circHIPK3 has yet to be investigated.  
1.8 CircHIPK3 in Disease 
 CircRNA function, regulation and mechanisms remain largely unstudied in cells 
however, there is increasing evidence of their abilities to act as RNA-binding protein and 
micro RNA (miRNA) sponges65,66. miRNAs are 19-25 nucleotide non-coding RNA’s 
which bind to the 3’ untranslated region (3’ UTR) of mRNA molecules67. miRNA act as a 
guide to the RNA-induced silencing complex (RISC), which leads to subsequent 3’-to-5’ 
mRNA degradation through Ago265,67. The polarity of linear mRNA is essential for 
endonuclease degradation. The lack of polarity of circRNA molecules renders circRNA 
inert to Ago2 cleavage when bound with miRNA65,68. CircRNA resistance to 
endonuclease likely contributes to their long half-life, > 24 h, and high stability in vivo. 




regulatory properties, acting primarily as an miRNA sponge. Through luciferase reporter 
assays and miRNA library screening, circHIPK3 has been proposed to interact with ~10 
miRNA across a variety of diseases and cell types. circHIPK3 has been studied in a 
variety of diseases, including diabetes, fibroblast differentiation, cancer and cardiac 
disease.  
1.8.1 CircHIPK3 in Diabetes   
 High-glucose has been proposed to regulate circHIPK3 expression both in vitro 
and in vivo72–74. circHIPK3 levels were increased in retinal endothelial cells of diabetic 
mice in a time dependent manner72. Further bioinformatics analysis lead to the 
determination that high glucose and oxidative stress can increase circHIPK3 expression 
through c-myb transcription factor72. Chromatin immunoprecipitation showed increase c-
myb binding to the promoter of HIPK3 gene during oxidative stress and high glucose 
conditions72.  In addition, c-myb silencing normalized circHIPK3 expression levels in 
high glucose mice. HIPK3 mRNA levels were not reported however, it could prove 
crucial to understand where circHIPK3 level under high glucose/oxidative stress is 
regulated at the parent gene, spliceosome or both. In vitro, overexpression of circHIPK3 
increased the viability, migration and proliferation of human retinal vascular endothelial 
cells (HRVECs)72. CircHIPK3 mechanism was proposed to act primarily through 
sponging miR-30 and affecting angiogenic factors such as endothelial growth factor-C 
(VEGFC), FZD4 and WNT2 signalling72. VEGFC, FZD4 and WNT2 are targets of miR-
30 and silencing/expression of circHIPK3 leads to angiogenic factor 
suppression/expression respectively. A second study using human serum showed a 




between circHIPK3 levels and neuropathic pain74. A diabetic rat model showed 
circHIPK3 to regulate inflammatory signalling through sponging miR-12474. In contrast, 
a recent study showed high-glucose in human umbilical vein endothelial cells (HUVECs) 
and diabetic patients experience decreased levels of circHIPK373. Primary human aorta 
endothelial cells showed similar downregulation of circHIPK3 induced by high-glucose 
diet environment73. Cao et al, 2018 propose that lower levels of circHIPK3 leads to 
increased miR-124 silencing leading to apoptosis and cell death73. Between both studies, 
it is clear that circHIPK3 functions as an miR-124 sponge to influence inflammatory 
signalling, however circHIPK3’s role as a potential diagnostic marker remains unclear.  
1.8.2 CircHIPK3 in Cancer 
To date, the most widely studied implication of circHIPK3 metabolism is its involvement 
in cancerous cell types and tissues, including prostate75,76 and bladder77,78.  
In prostate cancer, circHIPK3 was up regulated in prostate epithelial cells 
compared with normal tissue in humans75. circHIPK3 was shown to target miR-338-3p, 
altering extracellular matrix remodelling similar as in fibroblast differentiation. Based on 
miR-338-3p expression, circHIPK3 appears to be primarily upregulated in patients in 
stage III-IV, when compared with early stage patients75. A second study on prostate 
cancer confirmed circHIPK3 over expression and elucidate the role of miR-193a-3p and 
MCL1 regulation playing a role in cell apoptosis and proliferation76. A notable feature of 
circHIPK3 in cancer is its correlation with prognosis. circHIPK3 silencing attenuates 
tumor progression and size, thus circHIPK3 may be used as a predictor of progression 




 In bladder cancer, a similar trend with circHIPK3 was observed. CircHIPK3 
predicts and correlates with early stage bladder cancer prognosis and progression 
independently of the linear transcript78. However, one study provides evidence that 
circHIPK3 is downregulated in bladder cancer tissue and cell lines77. Li et al, 2017 
suggests that lower circHIPK3 expression leads to increased miR-558 expression, 
facilitating heparinase expression.  
1.8.3 CircHIPK3 and Fibroblast Differentiation 
 In addition to high-glucose environments, circHIPK3 has been shown to play a 
role in regulating fibroblast differentiation and proliferation79–81. In a lung fibrosis model, 
circHIPK3 is upregulated and plays a role regulating fibroblast to myofibroblast 
differentiation79. The increase in circHIPK3 expression leads to decreased miR-388-3p 
silencing by acting as a miRNA sponge79. miR-388-3p targets mRNA of SOX4; a key 
regulator of mesenchymal modelling, and COL1A1; a main component of the 
extracellular matrix79. Both SOX4 and COL1A1 are regulated through TGF- signaling 
and are corner stones of fibrosis. Adversely, circHIPK3 silencing and miR-338-3p 
overexpression markedly protect and reverse fibroblast differentiation both in vitro and 
vivo79. A similar study on cardiac fibrosis using an angiotension-II in vitro/vivo model 
shows parallel results; circHIPK3 is up-regulated in a fibrotic state and silencing of 
circHIPK3 attenuated fibrosis80. This evidence provides insight into circHIPK3 as a 
potential target of therapies for pulmonary and cardiac fibrosis.  
1.8.4 CircHIPK3 in Ischemia Reperfusion Injury 
Recently, two studies have been published investigating the role of circHIPK3 in 




expression was increased in human derived cardiomyocytes during short-term IRI82. 
Gain-of-function and loss-of-function studies showed that plasmid-based over-expression 
of circHIPK3 resulted in greater damage and increased cell death while siRNA attenuated 
injury. Bae et al. 2019 also showed that circHIPK3 increase exacerbated the expression of 
Bax and down-regulated Bcl-2, while sequestering the protective effects of miRNA-124-
3p, aggravating IRI in cardiac cells. A similar study was performed by Qiu et al. in 2021, 
in which they showed circHIPK3 expression increase leads to exacerbated apoptosis and 
autophagy during cardiac IRI83. The authors also showed increased Bax and reduced Bcl-
2 in cells over-expressing circHIPK3 during IRI and increased cleaved caspase 383. In this 
study, Qui et al. showed evidence that circHIPK3 interacts with miRNA-20b-5p and the 
interaction is responsible for these effects observed83. In contrast two studies showed the 
protective effects of circHIPK3 expression during myocardial IRI through activation of 
miR-29a/b pathway84,85. Wang et al. 2019 showed that circHIPK3 expression was 
increased in hypoxia induced exosomes86. Silencing of circHIPK3 lead to increased cell 
death and reversed the protective effects of hypoxia generated exosomes, while over-
expressing in the exosomes resulting in increased cell viability and enhanced the 
protective effects86. Wang et al. 2019 showed these effects were mainly contributed to the 
ability of circHIPK3 to sequester miR-29a and increasing IGF-1 expresssion86. Similarly, 
Cheng at al. 2021 showed a protective effect in IRI using high glucose conditions to 
induce circHIPK3 expression and AKT3 signalling85. circHIPK3 silencing lead to 
increased cellular apoptosis and an increase in proapoptotic genes through reduced 
sequestering of miR-29b, which was rescued by simultaneous over-expression of 




further investigation along with a standardized model to assess its cellular and molecular 
functions.  
 
 circHIPK3 has been implicated in many different mechanism and pathologies to 
date, most of which are quite recent. As the field of circRNA grows and new discoveries 
are made, the role of circHIPK3 in diseases will increase and its mechanisms made clear. 
A summary of the current development of circHIPK3 and its role in pathologies and 
miRNA targets can be found in Figure 1.5. 
 
Figure 1.5 Summary of different diseases and pathologies that circHIPK3 has been 




1.9 Hypothesis Statement 
 Based on the role of circHIPK3 in many pathologies and its recent involvement in 
IRI, we believe circHIPK3 is a strong therapeutic target for cardiac IRI during heart 
transplantation. We hypothesize that circHIPK3 expression is increased during IRI 
following cold storage and that silencing of circHIPK3 will lead to exacerbated injuries. 
We aim to test the hypotheses through two aims. 1) Investigate the role of circHIPK3 
expression on cell viability during IRI, 2) Investigate the underlying mechanism of 




Chapter 2. Materials and Methods  
2.1 Cell Culture  
Cardiomyocytes cell line HL-1 cells (Sigma-Aldrich, SCC065) were cultured according 
to the manufacturers protocol. Briefly, cells were maintained in Claycomb (51800C) 
complete medium (CM) supplemented with 0.1 mM Norepinephrine (Sigma-Aldrich, 
A0937), 10% HL-1 screened Fetal Bovine Serum (FBS, Sigma, TMS-016) 2 mM L-
glutamine (Wisent, 609-065-EL) and 1% Penicillin Streptomycin (P.S, Wisent, 450-200-
EL). Culture medium was changed everyday and sub-culture for experiments were 
maintained in transfection medium (TM), CM without antibiotic. 
2.2 Primary Cardiomyocyte Culture (PCM) 
Primary cardiomyocytes (PCMs) were isolated from neonatal C57BL/6 mice within 24 h 
of birth. Neonatal mice were aseptically sacrificed by decapitation according to animal 
use protocol (AUP 2019-147) approved by the subcommittee of Animal Care and Use of 
Western University. Hearts were aseptically excised and washed 4 times in cold D-Hanks 
buffer (Table 2.1) to remove blood or loose debris. Hearts were cut into small pieces, 
resuspended in 12.5 µg/mL Liberase (Roche, 05401151001) dissolved in D-hanks at 5 
mL/10 hearts and incubated for 5 min at 37°C in a water bath. Mixture was mixed with a 
transfer pipette to stimulate cell release and the supernatant was decanted. Liberase 
digestion was repeated at 37°C for 15 min 2x, each time hearts were mixed with a transfer 
pipette to stimulate release and the supernatant was collected into PCM-CM: DMEM/F12 
(Wisent, 319-085-CL) supplemented with 15% FBS, 2mM L-glutamine and 1% P.S. The 
digestion supernatants were spun down, and cells were resuspended in 1 mL/heart in 




fibroblasts to attach. After 2 h the medium was collected without disturbing attached cells 
and the cells were plated 1 heart/well in a 24-well plate pre-coated with 1% gelatin for 2 h 
at 37°C. Cells were cultured for 3-5 days with fresh medium daily. PCM beating was 
observed prior to any experiments. 
Table 2.1 1x D-Hanks recipe prepared for PCM isolation from neonatal C57/B6 mice. 
Component Concentration 
NaCl 140 mM 
KCl 5 mM 
CaCl2 1 mM 
MgSO4 • 7H2O 0.4 mM 
MgCL2 • 6 H2O 0.5 mM 
Na2HPO4 • 2H2O 0.3 mM 
KH2PO4 0.4 mM 
D-Glucose (Dextrose) 6 mM 
NaHCO3 4 mM 
 
2.3 Ischemia and Reperfusion Injury Model 
HL-1 cells were subjected to IRI using GENbag Anaerobic (Biomérieux, 45534) and 
Belzer UW cold storage solution (Fischer Scientific, NC0624127). Cells in multi-welled 
plates were cultured in normal cell culture conditions overnight. Cell Culture medium 
was removed and cells were washed with D-PBS (Gibco, 141190144), incubated with 




(Biomérieux, 96118). Bags were incubated for 30 min at 37C to activate anaerobic 
sachet followed by 24 h cold storage at 4C to mimic organ preservation. Following 
hypoxia, cells were reperfused by supplementing UW solution with an equal volume of 
TM up to 12 h at 37C. To mimic a similar cell death model in PCMs, 16 h cold storage 
at 4°C was used to induce hypoxia and 6 h reperfusion at 37°C with full replacement of 
UW solution with PCM-CM due to the more delicate nature of PCM compared to HL-1. 
2.4 CircHIPK3 siRNA mediated knockdown 
HL-1 cells were plated between 30,000-80,000 cells/well and incubated over-night (Table 
2.2). Cells were transfected with 1 μg:1 μL siRNA-Endofectin mix according to 
manufacturers protocol. Briefly, GL2 siRNA (5’-CGTACGCGGAATACTTCGA -3’, 
Sigma-Aldrich) or circHIPK3 siRNA (5’-CGCTACTACAGGTATGGCCTCA-3’, 
Sigma-Aldrich) was diluted in equal 50 µL Opti-MEM (Gibco, 31985070) and incubated 
5 min at room temperature (RT). Endofectin Max (GeneCopoeia, EF014) was diluted in 
equal volume Opti-MEM and followed the same incubation. siRNA and endofectin 
mixtures were combined and incubated for 15 min at RT. Cells were washed with D-PBS 
and cultured with Opti-MEM where 100 µL siRNA-endofectin mixtures were added for 6 
h at 37C. After 6 h, medium was supplemented with TM and cells were incubated for 24 
h – 48 h prior to harvesting for analysis or experiments. Exact amounts and volumes of 






Table 2.2 Detailed information and transfection reagent amounts for siRNA mediated 
knockdown in HL-1 cardiomyocytes. 











24 well 10,000/well 0.5:0.5 100 0.3 
12 well 30,000/well 1:1 200 0.8 
6 well 80,000/well 2:2 500 1.5 
 
2.5 Real-time Cell Death using an Incucyte System 
After induction of hypoxia, cell death was dynamically monitored during reperfusion 
from 0 h to 12 h using an incucyte to assess real-time cell death. Briefly, 1 µg/mL 
Propidium Iodide (PI, Thermo Fisher Scientific, P3566) was added to each well during 
reperfusion, 9 images of phase and red fluorescent were taken per well each hour at 4x 
magnification. Red objects indicate PI positive staining of DNA and cell death were 
counted per  well between the 9 images at each interval and plotted against time at each 
hour to generate cell death curve.  
2.6 Cell Apoptosis and Death Quantification by Flow Cytometry 
Following experimental endpoint, the culture supernatant was collected in a FACS tube, 
cells were washed with 500 µL PBS which was also collected. Cells were harvested with 
0.05% trypsin for 2 min at 37°C and neutralized with 1 volume CM. Cells were spun 
down x 500g 5 min at 4°C and washed with 1 mL cold Annexin V binding buffer 
(BioLegend, 420201) and spun again. Cells were resuspended in 100 µL Annexin V 




of 0.5 mg/mL PI and incubated for 15 min at RT in the dark. After incubation cells were 
diluted with 100 µL binding buffer and run on a CytoflexS (Beckman Coulter, Pasadena, 
California, USA) using the following laser gain for the respectively channels: 150 FSC, 
150 SSC, 200 APC-A, 5 ECD. Compensation was applied from mixed populations of 
viable and heat-killed cells at 95°C 5 min. 
 
2.7 RNA Isolation 
Total RNA was isolated from cells using QIAzol lysis reagents (Qiagen, 79306). Cells 
were washed with PBS and QIAzol was added directly to the monolayer. Cells were 
incubated at RT for 10 min prior to collect with a cell scraper. 1:5 volume chloroform 
was added to each tube, inverted 6 times and incubated 5 min at RT. Tubes were 
centrifuged at >18,000g for 15 min at 4°C and the top aqueous layer was removed and 
placed into a new tube with 1 volume isopropanol, inverted 6 times and incubated 5 min 
at RT. RNA was pelleted at 18,000g for 10 min at 4°C. Supernatant was decanted and 1 
mL 75% cold ethanol was added to wash, tubes were vortexed briefly to displace pellet, 
and spun again at 18,000g 5 min. The ethanol was decanted, tubes were briefly spun, and 
the remainder removed by pipette. Pellet was air dried 10-15 min, resuspended in 20-30 
µL RNase-free H2O (Invitrogen, 10977015) and heated at 55°C for 15 min to dissolve 
RNA. Concentrated was measured at 260nm using a microvolume spectrophotometer DS-
11 (Denovix, Wilmington, Delaware, USA). 
2.8 cDNA generation 
cDNA was generated using One Script Plus cDNA First strand kit (ABM, G236). Briefly, 




and diluted to 14.5 µL. Samples were incubated at 65°C for 5 min followed my ice for 2 
min. 4 µL 5x buffer was added along with 0.5 µL RNase OUT (40U/µL) and 1 µL 
reverse transcriptase enzyme. Samples were incubated at 25°C 10 min, 55°C for 15 min 
and 85°C 5 min. cDNA was diluted 10x by adding 180 µL RNase Free water.  
 
2.9 Quantitative Polymerase Chain Reaction (qPCR) 
qPCR was performed using BrightGreen 2x qPCR mastemix (ABM, mastermix-s) or 
BlastTaq 2x qPCR mastermix (ABM, G892) in 10 µL reaction. Briefly, 2 µL of diluted 
cDNA was incubated with 2x qPCR master mix, 200 nM forward/reverse primers, and 
incubated at 95°C 10 min, 40 cycles of 95°C 15s and 60°C 1 min on a CFX Connect 
(Bio-rad, Hercules, California, USA). In the case of low gene expression, up to 4 µL 
diluted cDNA was used in a 20 µL reaction. circHIPK3 was detected using divergent 
primers (Figure 2.1). A full list of primers used, and their sequences can be found in 
Table 2.3. To analyse gene expression, the delta-delta Ct method was used with GAPDH 





Figure 2.1 Divergent primers and their use to amplify circRNA across their back-splice 


























F: 5’- GGTGACCTGCTTTTTGGCTGt-3’ 
R: 5’- TTACGGTCAGGATGGGGTCT-3’  
Bak 
F: 5’- GGTGACCTGCTTTTTGGCTG-3’ 





F: 5’- CCTTGGATCCAGGAGAACGG-3’ 























F: 5’- CAGCTGAGAGGGAAATCGTG-3’ 
R: 5’- CGTTGCCAATAGTGATGACC-3’ 
 
2.10 CircHIPK3 primer validation 
circHIPK3 primers were validated using RNase R digestion protocol. Briefly, 5 μg of 
total RNA was digested with RNase R (ABM, E049) for 3 h at 37°C. Following 




described above. Following cDNA, qPCR was performed as described above for 
circHIPK3. Hipk3 and GAPDH. A mock digestion containing no RNase R was performed 
simultaneously to mimic control conditions. 2∆Ct between circHIPK3 or Hipk3 and mock 
digestion GAPDH cycling was used to represent enrichment or degradation of RNA 
levels. qPCR products were then sent for sanger sequencing (Robarts Research Institute, 
London, ON) to confirm back-splicing products.  
2.11 Lactate Dehydrogenase (LDH) Assay  
LDH assay was performed using a CytoTox 96 Non-radioactive cytotoxicity assay kit 
(Promega, G1780). Briefly, supernatant was collected at the desired timepoint from cells 
following IRI experiments described above. 50 µL of supernatant was mixed with 50 µL 
of CytoTox 96 reagent: substrate mix reconstituted in 12.5 mL of assay buffer, and 
incubated at room temperature for 30 min. After 30 min 50 µL of stopping solution was 
added to each well and the absorbance was measured at 490 nm. Absorbance of treatment 
groups were compared to normoxia supernatant as control levels of LDH. A blank 
containing fresh culture medium and a maximum positive control were included to ensure 
assay functionality.   
2.12 Protein Isolation and Western Blotting 
Cells were washed and collected in cold PBS, pelleted at 500g for 5 min at 4°C and the 
supernatant removed. Pellet was resuspended in cold RIPA lysis buffer (Cell signalling, 
9806) supplemented with 1 mM PMSF (Cell signalling, 8553S) and incubated on ice for 
20 min. Samples were spun at 18,000g for 20 min, the supernatant was collected and 5 µL 
was used to determine concentration using a Pierce BCA protein assay (Thermo 




To allow equal concentration of all samples and a greater amount of protein to be loaded 
in low-yield samples, 10-20 µg of protein was mixed with 5x volume of cold acetone 
(Caledon, 1201-2-10) and incubated at -20°C overnight to precipitate proteins . Proteins 
were pelleted at 18,000g for 10 min, dried, resuspended at 2 µg/µL in 1x loading buffer 
containing, 10% glycerol, 2% SDS, 0.1 M DTT, 0.01% Bromophenol blue in 0.375 M 
Tris-HCl, and boiled at 95ׄ°C for 5 min. 15 µg protein was loaded per well and run on a 
12% polyacrylamide SDS gel at 60V for 30 min followed by 1.5 h at 100V. Transfer was 
done using a trans-blot TURBO system (Biorad, Hercules, California, USA) according to 
manufacturers protocol. Membranes were blocked in 3% fat-free skim milk dissolved in 
PBST 0.1% tween-20 (Sigma-Aldrich, P9416) for 30 min at RT prior to addition of 
primary antibody in PBST + 1% BSA overnight at 4°C. A list of primary antibodies and 
their dilutions can be found in Table 2.4. Membranes were washed for 5 min 3x in PBST 
at RT prior to addition of secondary antibody, donkey anti-rabbit (Invitrogen, A16023) or 
goat anti-mouse (Invitrogen, A16066) in PBST, for 1.5 h at RT. Species reactivity and 
dilution of secondary antibody can be found in table 2.4. Membranes were washed again 
for 5 min 3x at RT in PBST prior to being exposed to an in-house ECL containing 1.25 
mM Luminol (Sigma-Aldrich, A8511), 2 mM 4-Iodophenylboronic acid (Sigma-Aldrich, 
471933), 5.4 mM H2O2 (Fischer Scientific, H325), in 100 mM Tris-HCl pH 7.2 for 2 min 
before imaging. Membranes were imaged in a FluoroChem M (Protein Simple, San Jose, 
California, USA) using chemiluminescence for protein bands and red fluorescence for 
protein marker. Bands with weak chemiluminescence were visualized using Clarity Max 
western ECL (Bio-rad, 1705062). After initial detected, membranes were washed 10 min 
in PBS and stripped using mild-stripping buffer; for 15 min 2x. Membranes were washed 




























Bax (1:1000) Rabbit 
Cell Signalling 
(2772) 
Bcl-XL (1:1000) Rabbit 
Cell Signalling 
(2764) 
P-MLKL (1:1000) Rabbit 
Cell Signalling 
(37333) 




Images were exported and densitometry was done using AlphaView Stand Alone or 
ImageJ density measurement. Briefly, bands were isolated and chemiluminescent 
intensity was normalized against B-actin from the same sample. Samples were then 
normalized against normoxia control bands. Phospho-proteins were normalized against 
their un-phosphorylated form prior to normalization against their normoxia controls.  
2.13 Statistical Analysis 
Statistical analysis was performed using GraphPad PRISM version 9.1.1. Students t-test 
or One-way ANOVA was performed, and data is represented as means ± SEM of a 




Chapter 3. Results 
3.1 CircHIPK3 expression increases during cardiac IRI  
 To determine the role of circHIPK3 in cardiac IRI, we used murine cardiomyocyte 
cell line HL-1 cells and built an in vitro IRI model. Using an incucyte system to monitor 
real-time cell death during reperfusion, we showed that our cold-storage and 
supplementation model caused HL-1 cells to die in a linear fashion compared to normoxia 
cells during reperfusion (Figure 3.1B). Using this model, we chose an early injury time 
point; 4 h, and a later injury time point; 8 h. Using our time points, we determined the 
expression of circHIPK3 and its parent gene Hipk3 qPCR. We found that circHIPK3 was 
up regulated at both 4 h an 8 h reperfusion (Figure 3.1C) where Hipk3 mRNA was not 
changed (Figure 3.1C), showing independent regulation between the circRNA and its 
home gene in HL-1 cells.  
 To confirm circHIPK3 expression during IRI, we used primary cardiomyocytes 
(PCMs) and induced IRI. circHIPK3 showed increased expression during IRI in PCMs 
(Figure 3.1D). However, Hipk3 mRNA expression was also increased in PCM (Figure 
3.1D) indicating independent regulation of circHIPK3 is not clear in primary cells.  
 To confirm the accuracy of circHIPK3 detection with our divergent primers, 
RNase R digestion was performed on total RNA. RNase R degrades linear RNA, 
destroying rRNA and mRNA leaving circRNA untouched. Following mock digestion 
RNA treatment, cDNA and qPCR for circHIPK3 and Hipk3, the 2∆Ct of Hipk3 was 
significantly larger than circHIPK3 (Figure 3.1E) showing higher expression in cells. 
Following RNase R digestion, there was an increase in 2∆Ct  of circHIPK3 and subsequent 




CircRNA fractions in total RNA and a decrease in linear mRNA. Sanger sequencing was 
conducted on qPCR products of circHIPK3 to confirm the existence of the back-splice 
junction sequence. Sanger sequencing showed the qPCR products matched Hipk3 exon 2 
at the back-splice junction (Figure 3.1F), where the 3’ end of exon 2 joins the 5’ end and 






Figure 3.1 Expression of circHIPK3 is increased during IRI. (A/B) Validation of 
IRI model inducing death, (C) expression of circHIPK3 and Hipk3 following IRI 
at 4 h and 8 h post reperfusion, (D) circHIPK3 expression in PCM following IRI 
at 6 h reperfusion, (E) Delta Ct values of circHIPK3 and Hipk3 following RNase 
R or mock digestion (F) Sanger sequencing of the back-splice sequence from 
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3.2 CircHIPK3 knockdown prior to IRI leads to increased cell death 
 To determine the role of circHIPK3 expression in cardiac IRI, we performed a 
loss-of-function assay through RNA interference. An siRNA (circHIPK3 siRNA) evenly 
spanning the back-splice junction of circHIPK3 was first designed, synthesized, and 
validated. HL-1 cells were transfected with circHIPK3 siRNA, or control GL2 siRNA and 
qPCR was conducted to measure the expression of circHIPK3 and Hipk3. It shows that 
circHIPK3 siRNA achieved more than 60% knockdown of circHIPK3 48 h after 
transfection but had no effect on Hipk3 mRNA levels compared to GL2 siRNA (Figure 
3.2A).  
 Next, we determined the effect of circHIPK3 knockdown on IRI. HL-1 cells were 
transfected with circHIPK3 siRNA 24 h prior to a 24 h cold ischemia (hypoxia) 
environment. Real time cell death was measured to evaluate IRI, using an incucyte 
system. We found circHIPK3 knockdown prior to IRI leads to significantly increased cell 
death during reperfusion (Figure 3.2B) when compared to GL2 siRNA. We found no 
difference in cell death between GL2 and circHIPK3 siRNA following cold storage, with 
a steep increase in red PI positive cells which are dead cells in circHIPK3 siRNA groups 
beginning 4 h post reperfusion (Figure 3.2B). There were also no observed changes in cell 
morphology prior to reperfusion (Figure 3.2C). Collectively, this indicates that the 
difference in cell viability is driven during the reperfusion phase.  
 Lactate Dehydrogenase (LDH) is commonly used as a biomarker for cardiac 
injury, including those involving ischemia induced damage. To further assess damage to 
our cells, we measured the relative free LDH in the supernatant of at 4 h reperfusion. We 




normoxia (Figure 3.2D), and that circHIPK3 siRNA groups had significant increased 
LDH compared to normoxia and GL2 siRNA (Figure 3.2D), indicating increased cellular 






Figure 3.2 CircHIPK3 
knockdown prior to IRI increases 
cell death and damage. (A) 
Selective knockdown of 
circHIPK3 independent from 
home gene, (B) Increases cell 
death during reperfusion 
following circHIPK3 siRNA 
knockdown, (C)  Phase and red 
fluorescent images showing loss 
of morphology and increased red 
PI positive dead cell, (D) LDH 
assay showing increased LDH in 
supernatant indicating cellular 
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3.3 CircHIPK3 knockdown leaves cells vulnerable to IRI  
To determine the mechanism behind circHIPK3 knockdown induced death in IRI, we 
transfected HL-1 cells with circHIPK3 siRNA for 48 h and analyzed pro- and anti- 
apoptotic gene expression. First, we analyzed mitochondrial based targets Bax, Bak, Bcl-
2 and Bcl-XL. circHIPK3 knockdown for 48 h led to a significant increase in pro-
apoptotic Bax gene in HL-1 cells (Figure 3.3A) and an increase in Bcl-2, a pro or anti 
apoptotic gene (Figure 3.3A). circHIPK3 knockdown had no effect on Bak or BclXL 
(Figure 3.3A). Second, we investigated downstream apoptotic caspases 3, 8 and 9. Our 
results show that CircHIPK3 knockdown induced a significant increase in caspase 3, 
caspase 8, and caspase 9 relatively to GL2 siRNA (Figure 3.3B). However, GL2 siRNA 
was slightly down regulated compared to control cells. This is likely contributed to the 
slight protective effect we observed from long-term culture with Opti-MEM in HL-1 
cells. To distinguish between apoptotic and necrotic cell death during IRI, we used 
Annexin V and PI staining to identify phosphatidyl-serine positive cells in early and late 
stage apoptosis using flow cytometry. We found that circHIPK3 silenced cells showed an 
increase in Annexin V positive staining at both 4 h and 8 h reperfusion, compared to 
normoxia and GL2 control (Figure 3.3C) and the percentage of Annexin V positive cells 
was increased in GL2 siRNA transfected cells compared to normoxia (Figure 3.3C). A 
similar trend was observed in PI staining, where GL2 and circHIPK3 siRNA groups had 
increased PI positive cells at 4 h and 8 h compared to normoxia (Figure 3.3D) and 
circHIPK3 siRNA exacerbated cell death compared to GL2 siRNA at 8 h only (Figure 
3.3D). Double positive Annexin V and PI cells indicating late-stage apoptosis had no 
significant change at 4 h reperfusion (Figure 3.3E) and only circHIPK3 siRNA group 
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Figure 3.3 CircHIPK3 knockdown leaves cell vulnerable to apoptosis. (A/B) 48 h 
knockdown of circHIPK3 leads to increase in proapoptotic gene mRNA levels. 
circHIPK3 knockdown leads to increase annexin V (C), PI (D) and double stained (E) 
positive cells at 4 h and 8 h reperfusion. (F) Quad plot showing PI vs annexin V 
staining following 8 h reperfusion. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001. 
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3.4 CircHIPK3 knockdown exacerbates apoptosis and necroptosis during IRI 
We previously showed that circHIPK3 knockdown leaves cells vulnerable to IRI through 
promoting apoptosis. To further investigate the mechanism of injury during IRI, we 
performed siRNA mediated knockdown of circHIPK3 prior to IRI, followed by RNA 
collection at 4 h reperfusion. circHIPK3 siRNA successfully downregulated circHIPK3 
after IRI while GL2 siRNA showed increase in circHIPK3 expression. (Figure 3.4A). We 
detected a small decrease in Hipk3 expression in GL2 siRNA transfected samples 
although not significant (Figure 3.4A). There was no significant change in Hipk3 
expression among the groups (Figure 3.4A). Similar to 48 h siRNA treatment without IR, 
we found exacerbated Bax expression in circHIPK3 knockdown IRI group compared to 
GL2 siRNA IRI group and normoxia (Figure 3.4B). Bax expression in GL2 siRNA 
groups was significantly increased compared to normoxia (Figure 3.4B), indicating that 
IRI further exacerbated Bax mRNA expression. Bak mRNA expression remained 
unchanged in both IRI groups (Figure 3.4B). We saw a similar trend at the protein level 
of Bax (Figure 3.4D). Compared to normoxia, GL2 and circHIPK3 siRNA IRI groups 
both induced Bax protein levels (Figure 3.4F), but no significant difference in protein 
express was detected between the two groups (Figure 3.4F). Bcl-2 mRNA levels 
following IRI shared an identical trend to 48 h siRNA transfection. circHIPK3 siRNA 
group following IRI induced Bcl-2 mRNA expression similar to siRNA alone (Figure 
3.3A & Figure 3.4B), but GL2 siRNA had no change (Figure 3.4B), indicating that Bcl-2 
expression increase is driven by circHIPK3 knockdown. Bcl-XL mRNA expression was 
unchanged in 48 h siRNA groups. During IRI, Bcl-XL mRNA shows decreased 




and normoxia groups. Bcl-XL mRNA showed no change in response to siRNA 
knockdown, yet the absence of loss in BclXL mRNA expression in GL2 siRNA IRI 
groups suggests decreased mRNA is not exclusively driven by IRI. At the protein level, 
we detected no change in Bcl-XL in GL2 or circHIPK3 siRNA groups compared to 
normoxia (Figure 3.4). 
 Caspase 3 and 9 showed no increase in mRNA expression in GL2 or circHIPK3 
siRNA IRI groups compared to normoxia (Figure 3.4C). Although no change was 
observed at the mRNA level, caspase 3 protein showed a significant increase in cleaved 
caspase 3 in both GL2 and circHIPK3 siRNA groups (Figure 3.4D-E). circHIPK3 siRNA 
group showed higher amount of cleaved caspase 3 than GL2 siRNA, although the 
difference was not significant (Figure 3.4E). Caspase 8 showed increased mRNA levels in 
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Figure 3.4 CircHIPK3 knockdown exacerbates cell death through activation of 
apoptosis. (A) qPCR showing circHIPK3 expression remains knocked down after 
siRNA and IRI compared to GL2 siRNA. circHIPK3 knockdown exacerbates 
mitochondrial proapoptotic and supresses anti –apoptotic (B) and increases caspase 
(C) mRNA levels. CircHipk3 knockdown exacerbates cleaved caspase 3 (D-E) but 
has no effect on bax (D,F) or Bcl-XL expression (D,G) *=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001. 
B-actin 




 Necroptosis exists as a pro-inflammatory cell death mechanism during IRI. To 
investigate the involvement of necroptosis, we performed western blotting for P-MLKL. 
Our results show that P-MLKL was up-regulated during IRI in both siRNA groups 
(Figure 3.5A-B) and exacerbated in circHIPK3 siRNA compared to GL2 siRNA (Figure 
3.5A-B). These results suggest that circHIPK3 knockdown exacerbates necroptosis cell 
death during IRI.  
 To further investigate the inflammatory response in cells, we measured TNFα, IL-
6 and IL-18 mRNA levels. TNFα showed a significant increase in both GL2 and 
circHIPK3 siRNA compared to normoxia (Figure 3.5C). TNFα mRNA levels in 
circHIPK3 siRNA IRI group slightly increased compared to GL2 siRNA group but the 
difference was not significant. IL-6 and IL-18 both showed increase in both GL2 siRNA 
and circHIPK3 siRNA compared to normoxia (Figure 3.5C), with no difference in IL-18 
mRNA levels between the two groups. We did observe a decrease in IL-6 mRNA levels 
in circHIPK3 siRNA groups compared to GL2 siRNA although it was not significant 
(Figure 3.5C). Overall, our results suggest circHIPK3 knockdown induces cell death 








































































































Figure 3.5 CircHIPK3 knockdown exacerbates necroptosis during IRI (A-B) 
circHIPK3 siRNA exacerbates MLKL phosphorylation during IRI, (C) qPCR 








Chapter 4. Discussion 
4.1 CircHIPK3 expression increases in myocardial IRI 
 The exact role of circHIPK3 in IRI remains controversial, with some studies 
suggesting knockdown protects against IRI82,83, while others suggest silencing aggravates 
myocardial IRI84–86. Due to the differences in cell lines, IRI models and the specific 
pathway of IRI investigated, it is nearly impossible to compare these studies to form a 
consensus.  Regardless of the affected pathways and consequential pathologies, it is clear 
that circHIPK3 expression is induced by IRI as reported by all studies, which is consistent 
with our findings.  
 Our results showed that following cold-storage cardiac IRI, circHIPK3 expression 
is increased approximately ~2.5-fold in HL-1 cardiomyocytes in early-stage reperfusion 
at 4 h and although not significant, to a lesser extent increased in later injury of 8 h. These 
results are consistent with previous studies showing circHIPK3 is up regulated in cardiac 
hypoxia and reoxygenation (H/R) models recently published82–86. We confirmed the 
expression of circHIPK3 in a PCM based model and found significant increase as well of 
~2-fold at 6 h. Previously it was shown that c-myb can bind to the Hipk3 gene promoter 
and increase circHIPK3 expression driven by high ROS. Although we do not confirm c-
myb driven expression of circHIPK3 here, in IRI it is known that ROS sharply increase 
indicating c-myb is likely a contributing factor72. However, our results also showed 
differential expression of circHIPK3 and Hipk3 during IRI in HL-1 cells, something not 
investigated by other studies. The observed differential expression suggests the c-myb 
driven expression is only part of the story, as we see selective back-splicing events to 




or Hipk3 negative feedback may also be influenced during IRI in HL-1 cardiomyocytes. 
We confirmed the increase of circHIPK3 in PCM model however, we did not see the 
same differential expression of circHIPK3 vs. Hipk3. Although we did not see the same 
level of differential expression between circHIPK3 and Hipk3 in PCM,  this could be 
contributed to differences in our models. Hipk3 acts as a protein kinase preventing 
Fas/FADD activation, key components in the extrinsic apoptotic signalling cascade. In 
our PCM model, we replace UW solution fully and reperfuse with complete medium 
only. This puts emphasis on ROS generation as the acidity in the solution and lactate 
build up is more readily cleared, thus it is possible to have low levels of TNFα and 
reduced extrinsic activation. Due to increased ROS generation, c-myb activation and 
reduction in extrinsic apoptosis, there may be less negative feedback on Hipk3 expression 
and a shift in splicing. However, there is currently no evidence suggesting a mechanism 
or regulation of differential expression between circHIPK3 and Hipk3 and therefore 
studies must be conducted to elucidate this mechanism.  
4.2 CircHIPK3 knockdown leads to increased cell death during IRI 
 Our IRI model showed increasing cell death in a linear fashion during reperfusion. 
Upon selective knockdown of circHIPK3 without silencing effects on Hipk3, we showed 
a significant increase in cell death during IRI. The difference in cell death was only 
visible starting at 4 h reperfusion as no difference was observed during hypoxia, 
indicating an apoptotic mechanism as opposed to necrosis. Our dynamic monitoring of 
cell death not only showed accelerated cell death during reperfusion, but the PI positive 
dot count and images suggest that after 8 h we had near complete cell death in the entire 




showed significant increase in Annexin V positive cells compared to GL2 siRNA 
following IRI at both 4 h and 8 h. The significant differences observed are consistent with 
our incucyte data suggesting increased cell death during IRI and indicates increased 
apoptosis, as Annexin V binds to phosphatidyl serine, a strong indicator of apoptosis. 
However, we did not observe or record > 40% of Annexin v positive cells. In addition, 
our forward and side scatter gating suggest that not all cells experience high side scatter, 
typically indicative of death, are annexin V positive. This suggests that although 
apoptosis is exacerbated, there may be other mechanism of death at work. 
4.3 CircHIPK3 as a suppressor of apoptosis 
To investigate the observed increase in cell death during IRI after circHIPK3 knockdown, 
we first looked to determine the effects of circHIPK3 knockdown on pro/anti apoptotic 
genes. We found that 48 h knockdown induced Bax and Bcl-2 mRNA expression 
significantly compared to GL2 siRNA. Although we did not observe any significant cell 
death upon transfection, this increase in expression indicates that although cells are not 
executing apoptosis, they are primed for the signalling cascade to occur and at a quicker 
rate. Increased Bax and Bcl-2 mRNA expression supports formation of the mPTP during 
high levels of ROS, exacerbating the intrinsic apoptotic pathway during IRI29,87. The 
increase in caspase 3, 8 and 9 mRNA observed in cells following siRNA treatment further 
supports this theory. The increase in caspase 9, being the final step in intrinsic apoptosis, 
would increase the extent of executor caspase activation. Upon mPTP formation and 
cytochrome C release, an increase in caspase 9 would result in increased caspase 3 
activation and subsequent apoptosis. The increase in caspase 8 suggests that the extrinsic 




for extrinsically stimulated apoptosis and leads to caspase 3 activation29,87. Collectively, 
this data along with the increase in caspase 3 mRNA, suggests that circHIPK3 
knockdown primes both apoptotic pathways for activation and decreases the stress 
threshold required for activation. 
4.4 CircHIPK3 knockdown promotes apoptosis through intrinsic signalling  
It has been previously reported that circHIPK3 silencing induced increased apoptosis and 
abolished protective effects during IRI84,85 and our knockdown studies confirmed the cells 
are more prone to apoptotic following circHIPK3 silencing. During IRI, we observed that 
these trends were maintained, especially with Bax expression being further exacerbated. 
As Bax mRNA levels rise during IRI in GL2 siRNA, we saw a concurrent rise in 
circHIPK3 siRNA groups indicating that it is the silencing driving this expression. 
Although no further exacerbation in Bcl-2 was observed, we observed a decrease in Bcl-
XL mRNA levels in circHIPK3 siRNA groups. The decrease in Bcl-XL mRNA levels 
was not observed during knockdown alone and is likely a factor of the increased 
apoptosis we observe. Essentially, as the cell commits to apoptosis and mPTP formation 
through Bax and Bcl-2 family members, the anti-apoptotic bcl-2 membranes such as Bcl-
XL will receive a negative feedback loop to decrease in expression32,34,87. At the protein 
level we did not observe differences in Bax expression between GL2 and circHIPK3 
siRNA groups nor did we observe any difference in Bcl-XL. Although no change in 
protein expression was observed, this does not directly represent the amount of mPTP 
formed. Since Bax expression was induced by circHIPK3 knockdown, if levels of Bax 




observed. However, studies involving mPTP formation under IRI following circHIPK3 
knockdown would be required to confirm this mechanism of action.  
 In addition to intrinsic apoptotic activation, we see increases in caspase 8 mRNA 
levels in both siRNA groups compared to normoxia group. Although we see activation of 
extrinsic apoptosis pathway, we do not see differences in caspase 8 mRNA between 
siRNA groups. During knockdown in absence of IRI, we saw increase in caspase 3, 8 and 
9 mRNA levels, however during IRI we only observed changes in caspase 8 mRNA. It is 
possible the increase in caspase mRNA levels following knockdown is a consequence of 
long-term silencing. During our knockdown studies we performed 48 h treatment as 
opposed to 24 h prior to IRI. During 48 h knockdown, the increased Bax expression may 
lead to slight mPTP formation, which result in leakage of ROS and subsequent activation 
of pro-apoptotic stimuli. This leakage may not be sufficient to activate apoptosis but may 
be responsible for the increase in pro-apoptotic mRNA expression. TNFα is a potent 
activator of extrinsic apoptosis29,31,35. During IRI there was no significant difference in 
TNFα expression between siRNA groups, indicating that exacerbated extrinsic apoptosis 
pathway is unlikely in this model as suggested by our caspase 8 mRNA results.  
 Taken together, this data suggests that circHIPK3 siRNA exacerbates intrinsic 
apoptosis signalling through increasing Bax and Bcl-2 expression, resulting in increased 
caspase 3 activation compared to control siRNA. Further studies investigating the effects 
of circHIPK3 on mPTP formation, mitochondrial stability and cytochrome C release are 




4.5 CircHIPK3 knockdown leads to increased necroptosis 
 Traditionally, necroptosis and extrinsic apoptosis are antagonistic, where caspase 
mediated cleavage of RIP1 and RIP3 results in inhibited necrosome formation and P-
MLKL formation. However, in our studies we show exacerbation of both P-MLKL and 
extrinsic apoptosis during IRI. Additionally, P-MLKL is enhanced following circHIPK3 
siRNA indicating that knockdown promotes necroptosis. The exacerbation of necroptosis 
following enhanced caspase 8 mRNA is a unique finding and represents a possible role of 
circHIPK3 in P-MLKL formation simultaneously with apoptosis. Although necroptosis is 
known to work through the RIP1/RIP3 pathway where caspase 8 activation can mediate 
its formation, it is presumed there are other checkpoints in place that could inhibit caspase 
8 degradation or promote necrosome formation that are not understood which circHIPK3 
may play a role in. 
4.6 Clinical Implications and Future  
 circHIPK3 has been gaining attention and showing promise as a regulator of 
disease in the past few years, with over 40 publications across multiple disciplines 
focusing on the role of circHIPK3 expression in disease. The clinical relevance of 
circHIPK3 expression has begun to be investigated in cancer and diabetes, where 
circHIPK3 expression is compared against disease prognosis and physiological 
features71,74, but the role of circHIPK3 in IRI at the clinical or in vivo level has yet to be 
investigated. In the current state, due to the controversial role of circHIPK3 expression on 
cell viability, the use of circHIPK3 as a biomarker is unlikely. However, the increase in 
circHIPK3 expression could potentially be used to determine if IRI occurs, as circHIPK3 




not the expression of circHIPK3 could be proportionate to ROS and extent of injury 
remains unknown.  
 At the current stage, circHIPK3 has no clear role in IRI at the clinical level 
however, the data of newly published papers suggest it may have a future. The role of 
circHIPK3 regulation in IRI has shown to have large implications for cellular viability in 
vitro. Our own data supports this claim where knockdown leads to almost complete cell 
death very quickly compared to GL2 siRNA. The large effects we see of circHIPK3 on 
cell death are indicative of a potential role as a strong therapeutic target for IRI. However, 
further studies elucidating the mechanism of circHIPK3 function and clinical 
applicability, such as correlation studies between circHIPK3 expression and IRI severity 
are required to determine circHIPK3 efficacy as a therapeutic target. 
4.7 Conclusion and Future directions 
 In conclusion, our results demonstrated that IRI up-regulates circHIPK3 
expression in cardiac cells and circHIPK3 siRNA increases cell death during IRI through 
exacerbation of necroptosis and intrinsic apoptotic pathways, leading to increase P-
MLKL phosphorylation and caspase 3 activation. Our results are in according with 
previous reports suggesting circHIPK3 expression in IRI provides protective effects and 
that the cellular response to increase ircHIPK3 is potentially protective. Our study shows 
strong evidence of gene regulation and pathway activation however, we do not show 
evidence of mPTP formation or necrosome formation. Therefore, we cannot conclude 
whether P-MLKL formation is caused by standard RIP signalling or an alternative 
mechanism. In addition, we did not observe Bax protein expression experiments 




increased prior to IRI or if the increase in protein is stimulated by IRI alone. In our study 
we did not show over-expression of circHIPK3 being protective as others have.  
 Overall, future studies further investigating the mechanism of action through 
apoptosis and necroptosis must be confirmed as well as using a synergistic heart 
transplant animal model to confirm deleterious or protective effects of circHIPK3 during 
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M.Sc Pathology and Laboratory Research    Fall 2019 to Present 
The University of Western Ontario, London, Ontario 
Bachelor of Science (Specialization in Biochemistry)               Fall 2015 to April 2019 
Laurentian University, Sudbury, Ontario  
 
RESEARCH EXPERIENCE 
M.Sc Pathology and Laboratory Research           September 2019 - Present 
The University of Western Ontario, London, Ontario 
The role of circHIPK3 in Ischemic Reperfusion Injury  
• Study the effects of circHIPK3 expression, knockdown and over-expression on cell viability 
during cardiac ischemia reperfusion injury 
• Characterize circHIPK3 expression and biogenesis in cardiac ischemic reperfusion injury 
• Investigate molecular mechanisms such as circRNA-miRNA and circRNA-Protein interactions 
using RNA immunoprecipitation (RIP) 
• Translate circHIPK3 in vitro experiments to in vivo animal transplant model 
Student Researcher              May 2017 – April 2019 
Laurentian University, Sudbury, Ontario 
Selective Method for Detection of H2Se production from mammalian tissue 
• Development of simple method to detect H2Se production from mammalian tissue lysate  
• Primary lead for all aspects of work including research direction  
Investigation on the Interplay of H2S/H2Se in Cardiac Hypertrophy  
• Study the interactions of H2S/H2Se systems in cystathionine gamma-lyase deficient mice and rat 
cardiomyocyte H9C2 cell line 
• Build a reactive oxygen species (ROS) induced cardiac hypertrophy model using rat 
cardiomyocyte H9C2 cell line  
• Use molecular techniques such as western blotting, PCR, fluorescent microscopy to study 










Department of Pathology and Laboratory Medicine, Western University, London, Ontario 
• Bowen Wang, Qinfeng Zhou, Anthony Li, Shuailong Li, Adam Greasley, Anton Skaro, Douglas 
Quan, Weiping Min, Kexiang Liu, Xiufen Zheng., 2021, Preventing alloimmune rejection using 
circular RNA FSCN1-silenced dendritic cells in heart transplantation. Journal of Heart and Lung 
Transplantation. 
 
• Yale Su, Cuilin Zhu, Bowen Wang, Hao Zheng, Vivian McAlister, James C Lacefield, Douglas 
Quan, Tina Mele, Adam Greasley, Kexiang Liu, Xiufen Zheng., 2020, Circular RNA Foxo3 in 
cardiac ischemia-reperfusion injury in heart transplantation: A new regulator and target. 
American Journal of Heart Transplantation.  
 
• Duo Zhao, Hao Zheng, Adam Greasley, Fengjun Ling, Qinfeng Zhou, Bowen Wang, Tiffany 
Ni, Ishita Topiwala, Cuilin Zhu, Tina Mele, Kexiang Liu, Xiufen Zheng., 2020, The role of miR-
711 in cardiac cells in response to oxidative stress and its biogenesis: a study on H9C2 cells. 
Cellular & Molecular biology letters. 9, 25:26  
Cardiovascular and Metabolic Research Unit, Laurentian University, Sudbury, Ontario 
• Greasley A, Belzile N, Yang G. H2S protects against cardiac cell hypertrophy through regulation 
of selenoprotein. Oxidative Medicine and Cellular Longevity. 2019  
Cardiovascular and Metabolic Research Unit, Laurentian University, Sudbury, Ontario  
• Bourque C, Zhang Y, Fu M, Racine M, Greasley A, Pei Y, Wu L, Wang R, Yang G*. H2S 
protects lipopolysaccharide-induced inflammation by blocking NFκB transactivation in 
endothelial cells. Toxicol Appl Pharmacol. 2017,338:20-29. 
COMMUNICATION & INTERPERSONAL SKILLS 
Hospital Volunteer                                February 2014 to April 2017 
Health Sciences North, Sudbury, Ontario 
• Greet patients/visitors and direct/bring them to the location that they need to be for their 
appointment/to visit a patient or assist them with any possible questions 
• Receive calls when volunteer assistance is required. Direct volunteers to the location where 
assistance is needed as well as document all volunteer activity for records   









Laurentian Stem Cell Club Founder/President                             January 2017 to Present  
Sudbury, Ontario 
• Organization of club, executive members, recruit new leaders and members 
• Organize swabbing events including location, supplies, volunteer schedule 
• Ensure all confidential swab kits were properly delivered to Canadian Blood Services 
 
TEACHING EXPERIENCE 
Teaching Assitant            January 2016 to April 2019 
Laurentian University, Sudbury, Ontario 
• Give directions to students performing in lab experiments in the fields of organic chemistry, 
biochemistry, and general chemistry 
• Assist in marking of students reports  
 
 
HONORS AND AWARDS 
• Ontario Graduate Scholarship (OGS)            2020 
• 1st place SOUSCC speaker Biology and Medicine Division         2019 
• 2nd place Laurentian University Mini-symposium           2019 
• CGS Masters NSERC, Ottawa University (Declined Offer)         2019 
• Promising Biochemistry Student Award              2018/2019 
• NSERC USRA (2x)                           2017/2018 
• Laurentian Academic Excellence Scholarship                               2015/2016/2017/2018 
 
